Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

e net sales, Schering- Plough's adjusted sales for the 2008 first quarter would have been $5.3 billion.

Overall, Schering-Plough shares in approximately 50 percent of the profits of the joint venture with Merck, although there are different profit-sharing arrangements for the cholesterol products in countries around the world. Schering-Plough records its share of the income from operations in "Equity income," which totaled $517 million in the 2008 first quarter, an increase of 6 percent versus $487 million in the first quarter of 2007. Schering-Plough noted that it incurs substantial costs such as selling, general and administrative costs that are not reflected in "Equity income" and are borne by its overall cost structure. There is a separate co-marketing agreement with Bayer for ZETIA in Japan, where the product was launched in June 2007.

Sales of Global Pharmaceuticals for the 2008 first quarter totaled $3.6 billion. Included in the first quarter of 2008 are $861 million in net sales related to Organon, the OBS human health business acquired in 2007.

Sales of REMICADE increased 36 percent to $507 million in the first quarter of 2008 due to continued market growth and expanded use. REMICADE is a treatment for inflammatory diseases that Schering-Plough markets in countries outside the United States (except in Japan and certain other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, pediatric Crohn's disease and ulcerative colitis.

Global sales of NASONEX, an inhaled nasal corticosteroid for allergies, rose 8 percent to $307 million versus the 2007 period, due to increased sales in international markets, partially offset by a decline in sales in the United States.

Sales of TEMODAR, a treatment for certain types of brain tumors, grew 20 percent to $236 million due to increased sales across all geographic regions.

Sales of PEGINT
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... FL (PRWEB) December 18, 2014 ... the nation’s leading specialty pharmacies, has an expanded ... as clinical pharmacy consultants for prescriber offices in ... expertise. , “We have a variety of ... For example, those specializing in hepatitis C help ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for ... Excellence in the Neurosciences (CEN), and professor of pharmacology ... as a member of the prestigious Dana Alliance for ... Maine to receive this honor. , The Dana ... the Dana Foundation. Its mission is to advance ...
(Date:12/19/2014)... 19, 2014 In contrast to traditional ... with various colors, Valoya uses proprietary LED technology to ... best possible uniformity which is critical in low proximity ... spectral accuracy throughout its lifetime which is up to ... , "The investment cost was clearly higher when ...
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... dental biomaterial market will grow moderately through 2023 ... procedures and growing awareness of dental biomaterials all spur ... markets such as China and ... will bring dental procedures within reach for a larger ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3
... TopSpin Medical,(TASE: TOPMD), the developer of a unique ... catheter for the coronary arteries,announced today the appointment ... Dr. Setum has over 15 years of ... She has a Ph.D. from the University of,Minnesota, ...
... PALO ALTO, Calif. and OSAKA, Japan, Oct. 17 ... Pharmaceutical Company Limited (TSE: 4502),today announced that they ... from the Licensing Executives Society of the U.S. ... develop and commercialize,Affymax,s lead product candidate, Hematide(TM), for ...
... transplant patients ... and their caregivers, ... Sheets: ALPMF), a leader in the field of transplantation, and,The ... a collaborative partnership to jointly,develop further materials for the multi-award-winning ...
Cached Biology Technology:TopSpin Medical Appoints Cindy Setum, Ph.D., Vice President Clinical Affairs 2Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 2Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 3Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... The University of Western Ontario, working in collaboration with ... line to reveal a previously unidentified mechanism contributing to ... Gros and Vania Prado of London, Canada and Silvia ... the neurotransmitter acetylcholine, a chemical messenger which slows cardiac ...
... around the world hasten to employ nanotechnology to ... manufacturing materials to creating new pharmaceutical drugs, a ... has shown that previous industrial revolutions, such as ... serious environmental impacts. Might nanotechnology also pose ...
... This release is available in Spanish . ... scientists are helping to increase understanding about the environmental ... potent antioxidant properties, in oat grain. Avns are ... many health benefits. The specific purpose of Avns inside ...
Cached Biology News:Genetically-modified mice reveal another mechanism contributing to heart failure 2Engineers explore environmental concerns of nanotechnology 2Engineers explore environmental concerns of nanotechnology 3Engineers explore environmental concerns of nanotechnology 4Engineers explore environmental concerns of nanotechnology 5Studies provide insight into key oat chemical 2
... flexible quadrupole MS detector optimized for HPLC ... and 2-D LC, as well as capillary ... drying gas system to create a finer ... low-to-medium polarity compounds, while providing for high ...
... is the ideal CO2 incubator for cell ... or embryos at or near body temperature. ... everything needed to protect and grow your ... stable incubation conditions ensure optimum culture growth. ...
... single-stranded DNA and RNA endonucleolytically to ... (DNA:DNA, DNA:RNA or RNA:RNA) are resistant ... concentrations of enzyme (1). The enzyme ... from double-stranded DNA (2), for selective ...
... DNA Ligation Kit enables ligation ... fragments in just 5 min ... on the DNA concentration, either ... concatemeric (high DNA concentration) ligation ...
Biology Products: